Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial (vol 8, pg 582, 2020)

被引：0
|
作者：
Cherney, D. Z. I.
Dekkers, C. C. J.
Barbour, S. J.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2020年 / 8卷 / 08期
关键词：
D O I：
10.1016/S2213-8587(20)30217-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E3 / E3
页数：1
相关论文
共 50 条
  • [31] Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
    Mordi, Natalie A.
    Mordi, Ify R.
    Singh, Jagdeep S.
    Baig, Fatima
    Choy, Anna-Maria
    McCrimmon, Rory J.
    Struthers, Allan D.
    Lang, Chim C.
    BMJ OPEN, 2017, 7 (10):
  • [32] The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
    Latva-Rasku, Aino
    Honka, Miikka-Juhani
    Kullberg, Joel
    Mononen, Nina
    Lehtimaeki, Terho
    Saltevo, Juha
    Kirjavainen, Anna K.
    Saunavaara, Virva
    Iozzo, Patricia
    Johansson, Lars
    Oscarsson, Jan
    Hannukainen, Jarna C.
    Nuutila, Pirjo
    DIABETES CARE, 2019, 42 (05) : 931 - 937
  • [33] Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial (vol 396, pg 909, 2020)
    Horne, A. W.
    Vincent, K.
    Hewitt, C. A.
    LANCET, 2020, 396 (10259): : 1334 - 1334
  • [34] The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
    van Bommel, Erik J. M.
    Muskiet, Marcel H. A.
    van Baar, Michael J. B.
    Tonneijck, Lennart
    Smits, Mark M.
    Emanuel, Anna L.
    Bozovic, Andrea
    Danser, A. H. Jan
    Geurts, Frank
    Hoorn, Ewout J.
    Touw, Daan J.
    Larsen, Emil L.
    Poulsen, Henrik E.
    Kramer, Mark H. H.
    Nieuwdorp, Max
    Joles, Jaap A.
    van Raalte, Daniel H.
    KIDNEY INTERNATIONAL, 2020, 97 (01) : 202 - 212
  • [35] Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril
    Del Vecchio, L
    Pozzi, M
    Salvetti, A
    Maschio, G
    Fusaroli, M
    Rovati, C
    Antonucci, F
    Cascone, C
    Scanferla, F
    Panichi, V
    Sturani, A
    Locatelli, F
    JOURNAL OF NEPHROLOGY, 2004, 17 (02) : 261 - 269
  • [36] Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial (vol 6, pg 370, 2018)
    Ludvik, B.
    Frias, J. P.
    Tinahones, F. J.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : E5 - E5
  • [37] Effects of Resveratrol Supplementation in Nrf2 and NF-κB Expressions in Nondialyzed Chronic Kidney Disease Patients: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial
    Saldanha, Juliana F.
    Leal, Viviane O.
    Rizzetto, Felipe
    Grimmer, Gustavo H.
    Ribeiro-Alves, Marcelo
    Daleprane, Julio B.
    Carraro-Eduardo, Jose C.
    Mafra, Denise
    JOURNAL OF RENAL NUTRITION, 2016, 26 (06) : 401 - 406
  • [38] Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase (vol 8, pg 762, 2020)
    Pivonello, R.
    Fleseriu, M.
    Newell-Price, J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (09): : e4 - e4
  • [39] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 369 - 384
  • [40] Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial
    Sadeghi, Sara
    Hakemi, Monir Sadat
    Pourrezagholie, Fatemeh
    Naeini, Fatemeh
    Imani, Hossein
    Mohammadi, Hamed
    TRIALS, 2024, 25 (01)
12345